Brief: Sensorion SENS-111 Fails To Meet Clinical Endpoint In Phase 2b Trial

Sensorion SA

02/12/2019 06:46

Dec 2 (Reuters) - SENSORION SA  ALSEN.PA :
    * SENSORION ANNOUNCES RESULTS FROM SENS-111 PHASE 2B TRIAL
IN
ACUTE UNILATERAL VESTIBULOPATHY
    * NO FURTHER ACTIVITIES RELATED TO SENS-111 WILL BE PURSUED
    * SENSORION WILL NOW FOCUS ON ADVANCING ITS HEARING LOSS
DISORDERS
PIPELINE
    * SAFE AND WELL TOLERATED IN 105 AUV PATIENT STUDY; PRIMARY
EFFICACY ENDPOINT NOT MET
    * SENS-111 WAS SAFE AND WELL TOLERATED BUT DID NOT MEET
PRIMARY
ENDPOINT OF VERTIGO INTENSITY
    * DISAPPOINTED THAT CLINICAL ENDPOINT WAS NOT MET
    * WILL NOW FOCUS ON FURTHER BUILDING OUR PIPELINE BY
CONCENTRATING
INVESTMENT IN ONGOING DEVELOPMENT OF SENS-401, CURRENTLY IN
PHASE 2 STAGE

Source text for Eikon:  ID:nBw1T09LMa 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))